ArticleCancers2022
Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Breast Cancer-Associated Venous Thromboembolism: Risk Factors, Mechanisms, and Clinical Management.Cancers · 2026Review
- Mapping the clinical topography and progression of venous thromboembolism in Chinese breast cancer surgical patients: a prospective longitudinal study.Breast cancer (Tokyo, Japan) · 2025Article
- Stanniocalcin2, A Promising New Target for Identifying Patients with Stroke/Ictus.International journal of molecular sciences · 2025Article
- Article
- Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.BMC cancer · 2024Article
- Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry.Breast cancer (Tokyo, Japan) · 2023Observational
- The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience.Cancers · 2023Article
- Venous thromboembolism incidence in postoperative breast cancer patients.Clinics (Sao Paulo, Brazil) · 2023Article
- Risk factors and potential predictors of pulmonary embolism in cancer patients undergoing thoracic and abdominopelvic surgery: a case control study.Thrombosis journal · 2022Article
- Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- Risk Factors of Venous Thromboembolism in Inpatients With Colorectal Cancer in China.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Venous Thromboembolism in Women with Breast and Gynaecological Cancers: What Do We Know and What Should We Do?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albeit it does not have the highest venous thromboembolism (VTE) incidence compared to other neoplasms, breast cancer contributes to many VTE events because it is the most diagnosed tumor in women. We aim to analyze the occurrence and timing of VTE during the follow-up of patients who underwent breast surgery, the possible correlated factors, and the overall survival. This retrospective study included all female patients diagnosed with mammary pathology and surgically treated in our clinic between January 2002 and January 2012. Of 5039 women who underwent breast surgery, 1056 were found to have no evidence of malignancy, whereas 3983 were diagnosed with breast cancer. VTE rate resulted significantly higher in patients with invasive breast cancer than in women with benign breast disease or carcinoma in situ. Invasive cancers other than lobular or ductal were associated with a higher VTE rate. In addition, chronic hypertension, high BMI, cancer type, and evidence of metastasis turned out to be the most significant risk factors for VTE in women who underwent breast surgery. Moreover, VTE occurrence significantly impacted survival in invasive breast cancer patients. Compared to women with benign mammary pathology, VTE prevalence in women with breast cancer is significantly higher. The knowledge about the risk factors of VTE could be helpful as prognostic information, but also to eventually target preventive treatment strategies for VTE, as far as the co-existence of invasive breast cancer and VTE has a significantly negative impact on survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.